Doubts about lutein
http://www.100md.com
《加拿大医疗协会学报》
I found it amusing that in the same issue in which one of CMAJ's editors educated Steve Arshinoff about the journal's new conflict of interest policy,1,2 there is a rambling opinion piece by Sylvia Santosa and Peter Jones on the possible benefits of lutein in the eye.3 I know the journal's policy had not taken effect at the time of submission, but I feel I must respond to the article.
To date, there has been no convincing research to show lutein supplementation to be of any real use in age-related macular degeneration. The evidence that lutein can slow the progression of cataracts is spotty at best, as demonstrated by the articles that are cited in this piece. The first reference is a review article,5 albeit of the data mined from the Beaver Dam Eye Study. Although the scope and size of the Beaver Dam Eye Study are laudable, it was not really a prospective study from which causality could be established. The nutritional information in the study was gathered using questionnaires, which are always subject to recall and compliance biases. The Beaver Dam Eye Study also suffered from "multiple looks": relationships were investigated for any and all possible population factors. The bottom line is that even though a role for lutein in treating age-related macular degeneration and cataracts was suggested in these two references, the studies don't demonstrate a cause-and-effect relationship. Plausibility is an important criterion for causality but it is not a sufficient one.
REFERENCES
Arshinoff S. Excluding the experts? [letter]. CMAJ 2005;173(8):849.
Choi S. Excluding the experts? [letter]. CMAJ 2005;173(8): 849.
Santosa S, Jones PJH. Oxidative stress in ocular disease: Does lutein play a protective role? CMAJ 2005;173(8):861-2.
Krinsky NI, Landrum JT, Bone RA. Biologic mecahnisms of the protective role of lutein and zeaxanthin in the eye. Ann Rev Nutr 2003;23:171-201.
Lyle BJ, Mares-Perleman JA, Klein BE, et al. Antioxidant intake and risk of incident age-related nuclear cataracts in the Beaver Dam Eye Study. Am J Epidemiol 1999;149:801-9.(Ari Giligson)
To date, there has been no convincing research to show lutein supplementation to be of any real use in age-related macular degeneration. The evidence that lutein can slow the progression of cataracts is spotty at best, as demonstrated by the articles that are cited in this piece. The first reference is a review article,5 albeit of the data mined from the Beaver Dam Eye Study. Although the scope and size of the Beaver Dam Eye Study are laudable, it was not really a prospective study from which causality could be established. The nutritional information in the study was gathered using questionnaires, which are always subject to recall and compliance biases. The Beaver Dam Eye Study also suffered from "multiple looks": relationships were investigated for any and all possible population factors. The bottom line is that even though a role for lutein in treating age-related macular degeneration and cataracts was suggested in these two references, the studies don't demonstrate a cause-and-effect relationship. Plausibility is an important criterion for causality but it is not a sufficient one.
REFERENCES
Arshinoff S. Excluding the experts? [letter]. CMAJ 2005;173(8):849.
Choi S. Excluding the experts? [letter]. CMAJ 2005;173(8): 849.
Santosa S, Jones PJH. Oxidative stress in ocular disease: Does lutein play a protective role? CMAJ 2005;173(8):861-2.
Krinsky NI, Landrum JT, Bone RA. Biologic mecahnisms of the protective role of lutein and zeaxanthin in the eye. Ann Rev Nutr 2003;23:171-201.
Lyle BJ, Mares-Perleman JA, Klein BE, et al. Antioxidant intake and risk of incident age-related nuclear cataracts in the Beaver Dam Eye Study. Am J Epidemiol 1999;149:801-9.(Ari Giligson)